Alexion Pharmaceuticals, Inc. (ALXN)

Check out top investors' recommendation for ALXN
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
158.20
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Apr 11, '18     170.00  Apr 11, '19  N/A 
Eric Schmidt Cowen And Company Buy   Apr 11, '18     163.00  Apr 11, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Mar 16, '18     149.00  Mar 16, '19  N/A 
Christopher Marai Wedbush Securities Inc. Buy   Mar 15, '18     156.00  Mar 15, '19  N/A 
Geoff Porges High Peaks Buy   Mar 15, '18     153.00  Mar 15, '19  N/A 
Geoff Porges High Peaks Buy   Feb 09, '18     153.00  Feb 09, '19  N/A 
Matthew Harrison UBS Buy   Feb 09, '18     151.00  Feb 09, '19  N/A 
Robyn Karnauskas Deutsche Bank Securities Buy   Feb 09, '18     170.00  Feb 09, '19  N/A 
Ian Somaiya Piper Jaffray Buy   Feb 08, '18     180.00  Feb 08, '19  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Feb 08, '18     170.00  Feb 08, '19  N/A 
Eric Schmidt Cowen And Company Buy   Feb 08, '18     163.00  Feb 08, '19  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Feb 08, '18     151.00  Feb 08, '19  N/A 
Alethia Young Deutsche Bank Securities Buy   Jan 17, '18     147.00  Jan 17, '19  N/A 
Eric Schmidt Cowen And Company Buy   Jan 08, '18     180.00  Jan 08, '19  N/A 
Geoff Porges High Peaks Buy   Dec 06, '17     169.00  Dec 06, '18  N/A 
Christopher Raymond Robert W. Baird & Co., Inc. Buy   Dec 04, '17     170.00  Dec 04, '18  N/A 
Eric Schmidt Cowen And Company Buy   Nov 30, '17     180.00  Nov 30, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Nov 01, '17     166.00  Nov 01, '18  N/A 
Eric Schmidt Cowen And Company Buy   Oct 26, '17     180.00  Oct 26, '18  N/A 
Matthew Harrison UBS Buy   Oct 24, '17     153.00  Oct 24, '18  N/A 
< previous123456